Clients turn to us for commercially focused advice on structuring, negotiating, and executing IP-rich transactions. Protecting innovation, unlocking new revenue streams, shaping IP rights into valuable business assets and managing risk are at the heart of every deal.
Typical needs include securing robust licensing agreements, navigating complex collaborations, managing joint ventures and conducting thoughtful IP due diligence. Our team supports clients across industry sectors and jurisdictions. Our approach is collaborative and tailored, drawing on deep sector insight and seamless cross-border support.
Winner: Trademark Transactions Firm of the Year, United Kingdom’
IAM & WTR - The Global Awards 2024
Clients value our ability to anticipate challenges and deliver clear, outcome-driven strategies that protect their interests and unlock opportunities in rapidly evolving landscapes.
我们的服务
Recent experience includes:
- Advised Bicycle Therapeutics in parallel on strategic collaboration agreements with each of Novartis and Bayer. The companies will develop, manufacture and commercialise Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets. Under the terms of each agreement, Bicycle will use its proprietary phage platform to discover "Bicycles" to be developed into BRCs. Novartis and Bayer are responsible for further development, manufacture and commercialisation of the BRCs. Bicycle received US$50 and US$45 million upfront payments respectively. It is also eligible to receive development and commercial-based milestone payments totalling up to US$1.7 billion under each agreement, as well as tiered royalties on Bicycle®-based medicines commercialised by Novartis and Bayer.
- Advised BenevolentAI on its strategic collaboration with Merck. The collaboration will use BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates – initially for three targets in oncology, neurology and immunology – and to identify and develop innovative compounds through Hit Identification to pre-clinical stage. Under the terms of the agreement, BenevolentAI will be eligible for payments of up to $594 million, consisting of a low double-digit million-dollar upfront payment on signing and then potentially discovery, development and commercial milestones. Tiered royalties will also be payable on net sales of any commercialised products.
- Advised GE HealthCare in relation to its exclusive out-licence to SonoThera of GE HealthCare's Optison and Sonazoid Microbubble Products for use with the SonoThera Ultrasound-guided gene therapy platform. The worldwide licence agreement allows the microbubble products to be used in the development and commercialisation of Sonothera's novel, ultrasound-guided, nonviral, gene therapy platform. The platform intends to use microbubble-mediated biophysical process to noninvasively deliver nucleic acid payloads of diverse formats and sizes to selectively target a wide range of organs within the body. SonoThera is in preclinical development of its technology, preparing for phase 1 clinical trials.
- Advised one of the UK's leading soft drink manufacturers in relation to a collaboration and licensing arrangement for the development of new flavouring technology.
- Advise Swiss-based On in relation to collaboration, R&D and related agreements and matters with respect to the development of On's world famous performance running shoes.
